



UNIVERSITY OF  
BIRMINGHAM

# The radiobiology of protons and high-LET radiation in head and neck cancer and glioblastoma cell models




Professor Jason Parsons  
Institute of Cancer and Genomic Sciences  
School of Physics and Astronomy



National Institutes of Health  
*Turning Discovery Into Health*



# The advantages but also biological uncertainties following proton beam therapy (PBT)



Taken from Paganetti and van Luijk (2013) Sem Rad Oncol


- Further research exploiting the biological impact of PBT is vital for establishing RBE and optimal clinical treatment for tumours.

# Head and neck squamous cell carcinoma (HNSCC) and glioblastoma (GBM)

## HNSCC

- 6<sup>th</sup> most common cancer worldwide (~800,000 cases/year).
- Major contributory factors are smoking and drinking.
- Rapid rise in incidence of human papillomavirus (HPV-16) associated cancers of the oropharynx (~60 % of OPSCC and ~40 % of HNSCC combined).
- HPV-positive tumours are more sensitive to radiotherapy and chemotherapy, thus improved prognosis, than HPV-negative tumours.

Head and Neck Cancer Regions



## GBM

- The most common primary brain tumour in adults.
- Survival rates are extremely poor (median of ~12 months).
- Conventional radiotherapy has limited effectiveness.






# Major research questions/aims

- Do protons, particularly at increasing LET, lead to changes in the molecular (DNA) and cellular (survival/RBE) profiles.
- Can the effectiveness of protons (particularly at high-LET) be further exacerbated using drugs/inhibitors.
- What is the impact of reduced oxygen (hypoxia) on photon versus proton efficacy.
- What is the effect of dose rate (FLASH) on proton radiobiology.

# Major research questions/aims

- Do protons, particularly at increasing LET, lead to changes in the molecular (DNA) and cellular (survival/RBE) profiles.
- Can the effectiveness of protons (particularly at high-LET) be further exacerbated using drugs/inhibitors.
- What is the impact of reduced oxygen (hypoxia) on photon versus proton efficacy.
- What is the effect of dose rate (FLASH) on proton radiobiology.



# “Relatively” high-LET protons cause a decrease in HNSCC cell survival due to CDD formation compared to low-LET protons



58 MeV (1 keV/ $\mu$ m); 11 MeV (12 keV/ $\mu$ m)

\*p < 0.02, \*\*p < 0.01, \*\*\*p < 0.005, \*\*\*\*p < 0.001







# “Relatively” high-LET protons cause a decrease in GBM cell survival due to CDD formation compared to low-LET protons




\*p<0.02, \*\*p<0.005, \*\*\*p<0.002

# Modulation of proton-induced cellular sensitivity following

## DUB siRNA knockdown






# Modulation of proton-induced cellular sensitivity following DDR siRNA






# Targeting OGG1 and PARG sensitises cells to high-LET protons

*HeLa*




*FaDu*





- DMSO (11 MeV)
- DMSO (11 MeV; mod.)
- TH5487 (11 MeV)
- TH5487 (11 MeV; mod.)
- PDD00017273 (11 MeV)
- PDD00017273 (11 MeV; mod)

\*p<0.05, \*\*p<0.01,  
\*\*\*p<0.001, \*\*\*\*p<0.0001










*FaDu*



# **Major research questions/aims**

- Do protons, particularly at increasing LET, lead to changes in the molecular (DNA) and cellular (survival/RBE) profiles.
- Can the effectiveness of protons (particularly at high-LET) be further exacerbated using drugs/inhibitors.
- What is the impact of reduced oxygen (hypoxia) on photon versus proton efficacy.
- What is the effect of dose rate (FLASH) on proton radiobiology.







# Hypoxia-induced radioresistance and identifying strategies to overcome this using high-LET radiation



# DDR inhibitors can sensitise hypoxic GBM, but not

## HNSCC, cells to photon irradiation

AZD1390 (ATMi)  
AZD6738 (ATRi)  
AZD7648 (DNA-Pkcsi)




# **Major research questions/aims**



- Do protons, particularly at increasing LET, lead to changes in the molecular (DNA) and cellular (survival/RBE) profiles.
- Can the effectiveness of protons (particularly at high-LET) be further exacerbated using drugs/inhibitors.
- What is the impact of reduced oxygen (hypoxia) on photon versus proton efficacy.
- What is the effect of dose rate (FLASH) on proton radiobiology.

**Wait for the next talk!**


# Current radiobiology research focus





High flux accelerator neutron source for BNCT



Development of patient-derived organoids  
(Inge Tinhofer-Keilholz – Charité Berlin)



Transcriptomic and proteomic analysis post-irradiation



Development of chick embryo model

R01CA256854-01

# Summary and key points

- High-LET protons (at Bragg peak distal end), in contrast to low-LET protons, can generate complex DNA complex that contributes to increased cellular radiosensitivity.
- Repair of complex DNA damage induced by high-LET protons is co-ordinated through a specific cellular DNA damage response involving PARP-1, PARG and OGG1.
- Opportunities for exacerbating HNSCC cell killing effects of photons and protons (both low and high-LET) through specific DNA repair inhibitors.
- Other biological factors (hypoxia) and physical factors (dose rate/FLASH) require further investigation.

# Acknowledgements

## Parsons Group

Rachel Carter

Katie Nickson

Terpsi Vitti

Maria Rita Fabbrizi

Jonathan Hughes

Alice Ormrod

Chun Li

Lizzie Dufficy

Amalia Goula

Karthik Vaidya

Rhianna Hill

George Duffield

Emma Melia

Leah Punshon

Laura Hawkins

Alex Bembridge



UNIVERSITY OF  
BIRMINGHAM

Stuart Green

Tzany Kokalova-Wheldon

Ben Phoenix

Tony Price

Hisham Mehanna

Colin Watts

**University of Glasgow**

Anthony Chalmers

**Clatterbridge Cancer Centre**

Andrzej Kacperek

**Charité, Berlin**

Inge Tinhofer-Keilholz



**Oxford Institute for  
Radiation Oncology**

Mark Hill

James Thompson

Kristoffer Petersson

**University of Liverpool**

Mike Clague, Sylvie Urbe

Sonia Rocha, Terry Jones

**Imperial College London**

Ken Long

**AstraZeneca**

Stephen Durant

Alan Lau

**Thanks to**

Helen Bryant

Thomas Helleday



National Institutes of Health  
*Turning Discovery Into Health*



**The Clatterbridge  
Cancer Centre**  
NHS Foundation Trust

